·  Our Group was founded.

· We began to collaborate with GSK to market and sell Zinacef injection and Zinacef tablet in China.

· We obtained the exclusive right from Amarin to develop and commercialize Vascepa in Greater China.

· We obtained the exclusive right from Eli Lilly to market and sell Vancocin and Ceclor in China.

· We completed the acquisition of the product rights of Vancocin in China and Italy and Ceclor in China as well as the production facility of Ceclor in Suzhou from Eli Lilly.

· We obtained the exclusive right to market and sell Mulpleta in Mainland China, Hong Kong and Macau from Shionogi.

· We completed the acquisition of the product rights of FPN in China and the Netherlands from GSK.

· The NMPA accepted for review the NDA for Vascepa in February 2021 and Mulpleta in November 2021, respectively.

· The CDE began the second-round technical review for Vascepa and Mulpleta.

· We received Approval of Vascepa to Reduce Cardiovascular Risk in Hong Kong,China.

· The Phase III study results of Mulpleta were published on Hepatology International which demonstrated its efficacy and safety in Chinese patients with CLD-associated TCP.

· The NMPA has approval for VASCEPA as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL)(VHTG).

· The NMPA has approved Mulpleta (Lusutrombopag Tablets) for the adult patients with chronic liver disease accompany thrombocytopenia who are scheduled to undergo an operation procedure (including diagnostic procedure) (CLD) as an import drug on 27th June.

· The NMPA has approval VASCEPA (Icosapent Ethyl) for new cardiovascular risk reduction(CVRR) indication in Mainland China.